a portfolio of active substances, in clinical stages
Phase II
Phase II/III
Study launch
Results
TOTUM-63 / Prediabetes
Mid-2020
S1 2022
TOTUM-070 / Hypercholesterolemia
Q4 2020
Q4 2021 / Q1 2022
TOTUM-854 / Arterial hypertension
Q1 2021
2022
TOTUM-448 / Fatty Liver
S2 2021
-
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Valbiotis SA published this content on 02 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 February 2021 10:03:01 UTC.
VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. Valbiotis specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. Valbiotis is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception Valbiotis has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.